ICCM

NASDAQ

IceCure Medical Ltd.

SectorHealth CareIndustryMedical/Dental Instruments

News25/Ratings2

IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.

News · 26 weeks69-83%

2025-10-262026-04-19

Mix4990d

SEC Filings18(37%)
Other13(27%)
Insider12(24%)
Earnings3(6%)
Leadership2(4%)
Offering1(2%)

Latest news

25 items

1dSEC
SEC Form 6-K filed by IceCure Medical Ltd.
6-K - IceCure Medical Ltd. (0001584371) (Filer)
2dSEC
SEC Form 6-K filed by IceCure Medical Ltd.
6-K - IceCure Medical Ltd. (0001584371) (Filer)
2dPR
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in
11dSEC
SEC Form EFFECT filed by IceCure Medical Ltd.
EFFECT - IceCure Medical Ltd. (0001584371) (Filer)
22dSEC
SEC Form F-1 filed by IceCure Medical Ltd.
F-1 - IceCure Medical Ltd. (0001584371) (Filer)
23dSEC
SEC Form D filed by IceCure Medical Ltd.
D - IceCure Medical Ltd. (0001584371) (Filer)
27dSEC
SEC Form 424B5 filed by IceCure Medical Ltd.
424B5 - IceCure Medical Ltd. (0001584371) (Filer)
27dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by IceCure Medical Ltd.
SCHEDULE 13D/A - IceCure Medical Ltd. (0001584371) (Subject)
27dSEC
SEC Form 6-K filed by IceCure Medical Ltd.
6-K - IceCure Medical Ltd. (0001584371) (Filer)
28dPR
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent fees and other offering expenses. In addition, in a concurrent private pla
29dINSIDER
SEC Form 3 filed by new insider Malca Yonatan
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Huang Yang
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Chan Vincent Chun Hung
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Tel-Tzure Tlalit Bussi
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Levav Shay
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Levita Sharon
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Good Shad
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Tsimerman Ronen
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Mayron Ron
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Muchnik Naum
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Dotan Merav Nir
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dINSIDER
SEC Form 3 filed by new insider Shamir Eyal
3 - IceCure Medical Ltd. (0001584371) (Issuer)
29dSEC
SEC Form 6-K filed by IceCure Medical Ltd.
6-K - IceCure Medical Ltd. (0001584371) (Filer)
29dPR
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study populationFull analysis of results to be presented at European Conference of Interventional Oncology 2026 in Basel, SwitzerlandData supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe CAESAREA, Israel, March 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by
30dSEC
SEC Form EFFECT filed by IceCure Medical Ltd.
EFFECT - IceCure Medical Ltd. (0001584371) (Filer)